Our Team

The only source of knowledge is experience. - Albert Einstein

A++ / A--

Mr. Frank Menzler, Analyst-Advisor, Medical Devices and Health Sciences, is an accomplished executive and entrepreneur with US and international experience spanning 15-plus years. Mr. Menzler brings medical device and life science research, development, and sales and marketing management experience, which spans the globe and ranges from early stage start-ups to executive positions with multi-billion dollar corporations.

Mr. Menzler co-founded Impella Cardiotechnik AG (Germany), helping raise more than $30 million in grants and venture capital for the nation’s first-ever academically-sponsored research effort to receive private venture capital funding. Impella, a medtech start up venture, successfully designed, developed, and ultimately commercialized minimally-invasive cardiac assist systems for use in cardiology and cardiac surgery. Impella manufactured and marketed intracorporeal micro blood pumps with technology protected by more than 30 European and international patents. In 2000, the Company was honored with innovation awards by the City of Aachen and German Commerce and was added to the list of the World’s 40 Leading Technology Pioneers in February 2003 by the Davos World Economic Forum as one of only two German companies to reach this milestone. In 2005, Impella was acquired by US-based, ABIOMED, Inc., the global leader for products in the acute heart failure market, shipping more ventricle assist devices (VADs) than any other company in the world.

Among his European appointments, Mr. Frank Menzler served as Marketing Manager for Europe, Middle East, Africa and Canada (EMEAC) at Guidant Corporation’s, Cardiac Surgery Business Unit in Brussels, Belgium. During his tenure at Guidant, he increased revenue substantially and restructured the Cardiac Surgery EMEAC Organization. Guidant was subsequently acquired for $27.5 billion by Boston Scientific Corporation.

In the United States, Mr. Menzler served as Director, International Distributors, at ABIOMED, Inc., developer of the world’s first completely self-contained total artificial heart, and a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Previously, Frank Menzler served as General Manager for the company’s European division.

As Chief Executive Officer of start-up, HepaLife Technologies, Inc., Mr. Menzler grew the company from its early research focus on a single stem cell line to eventually acquiring a $60 million-plus cell-based liver device, the most advanced in the world. He raised $7 million and successfully transformed the company from an early-stage research firm to clinical Phase III trials, ultimately effecting a multi-million merger with a hydrogels manufacturer. He successfully in/out-licensed and undertook research and development partnerships with the United States Department of Agriculture, United States Army, United States Navy, and with NASA’s International Space Station National Laboratory Initiative (on board the Space Shuttle ‘Endeavour’ with USDA; mission STS-126).

At Fraunhofer USA, Mr. Menzler serves as Senior Director USA, Heinrich Hertz Institute where he is working to identify new technology applications for the American market. Fraunhofer is Europe’s largest application-oriented research organization with 80 independent research units, 20,000 staff and a $2.5 billion budget.

Mr. Frank Menzler holds a Master’s degree in Business Administration (MBA) from Northwestern University’s Kellogg School of Business and a Diplom-Ingenieur (Master’s of Science equivalent) in Mechanical and Biomedical Engineering from RWTH Aachen, Germany’s largest university of technology and one of Europe’s leading technology institutions, renowned for its standards of education and research excellence since 1870.